Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 49 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung CancerCompletedNCT00231465Phase 2Results posted
• OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung CancerCompletedNCT00230126Phase 2Results posted
• IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT00229723Phase 2Results posted
• Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By SurgeryCompletedNCT00227760Phase 2Results posted
• An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing ChemotherapyCompletedNCT00226811Phase 2Results posted
• Lapatinib in Metastatic Breast Cancer Resistant to Hormone TherapyTerminatedNCT00225758Phase 2Results posted
• AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic CancerCompletedNCT00219557Phase 2Results posted
• S0505 Sorafenib in Treating Patients With Advanced Soft Tissue SarcomasCompletedNCT00217620Phase 2Results posted
• Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast CancerCompletedNCT00217399Phase 1/2Results posted
• Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular ResponseTerminatedNCT00210119Phase 2Results posted
• Neoadjuvant GW572016 to Treat Breast CancerCompletedNCT00206427Phase 2Results posted
• Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus ErlotinibCompletedNCT00203424Phase 2Results posted
• Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid TumorsCompletedNCT00195260Phase 1Results posted
• Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell CarcinomaCompletedNCT00193258Phase 1/2Results posted
• Docetaxel Plus Imatinib Mesylate in Metastatic Breast CancerCompletedNCT00193180Phase 2Results posted
• Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain TumorsCompletedNCT00187486Phase 2Results posted
• Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic CancerCompletedNCT00185588Phase 1/2Results posted
• Sorafenib in Treating Patients With Extensive Stage Small Cell Lung CancerCompletedNCT00182689Phase 2Results posted
• An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ LeukemiaCompletedNCT00171249Phase 2Results posted
• An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-AlphaCompletedNCT00171223Phase 2Results posted
• An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast CrisisCompletedNCT00171158Phase 2Results posted
• A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux DiseaseCompletedNCT00165646Phase 3Results posted
• Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic CancerCompletedNCT00161213Phase 2Results posted
• Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive GlioblastomaCompletedNCT00154375Phase 3Results posted
• Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00153803Phase 3Results posted
• Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 WeeksCompletedNCT00147498Phase 2Results posted
• Study Evaluating HKI-272 in TumorsCompletedNCT00146172Phase 1Results posted
• Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck CancerCompletedNCT00140556Early Phase 1Results posted
• Erlotinib in Women With Previously Untreated Adenocarcinoma of the LungCompletedNCT00137839Phase 2Results posted
• Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal TumorCompletedNCT00137449Phase 2Results posted
• Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate CancerCompletedNCT00137436Phase 1/2Results posted
• Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell CancerCompletedNCT00137423Phase 2Results posted
• Therapy for Newly Diagnosed Patients With Acute Lymphoblastic LeukemiaCompletedNCT00137111Phase 3Results posted
• Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's LymphomaCompletedNCT00131937Phase 2Results posted
• Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine TumorsCompletedNCT00131911Phase 2Results posted
• Bevacizumab and Erlotinib Study in Advanced Ovarian CancerCompletedNCT00130520Phase 2Results posted
• Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)CompletedNCT00129740Phase 2Results posted
• Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney CancerTerminatedNCT00126659Phase 2Results posted
• Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney CancerCompletedNCT00126594Phase 2Results posted
• Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung CancerCompletedNCT00126581Phase 2Results posted
• Sorafenib in Treating Patients With Advanced Anaplastic Thyroid CancerTerminatedNCT00126568Phase 2Results posted
• Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin CancerCompletedNCT00126555Phase 2Results posted
• Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney CancerCompletedNCT00126503Phase 1/2Results posted
• Study of Tarceva and Targretin in Stage I-II Lung CancerCompletedNCT00125372Not applicableResults posted
• Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung CancerCompletedNCT00125359Phase 2Results posted
• Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)TerminatedNCT00124748Phase 3Results posted
• Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed GliomaCompletedNCT00124657Phase 1/2Results posted
• Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CMLCompletedNCT00123487Phase 3Results posted
• Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CMLCompletedNCT00123474Phase 3Results posted
• An Open Label Dose Escalation Study Of E7080CompletedNCT00121719Phase 1Results posted
• Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney CancerCompletedNCT00121251Phase 1/2Results posted
• BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell CarcinomaCompletedNCT00117637Phase 2Results posted
• Trial Evaluating Gleevec in Patients With Anaplastic Thyroid CarcinomaTerminatedNCT00115739Phase 2Results posted
• Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic CancerCompletedNCT00114244Phase 2Results posted
• Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell CarcinomaCompletedNCT00113529Phase 1/2Results posted
• A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung CancerCompletedNCT00113516Phase 2Results posted
• Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal CancerCompletedNCT00113373Phase 2Results posted
• Sorafenib in Treating Patients With Regional or Metastatic Cancer of the UrotheliumTerminatedNCT00112905Phase 2Results posted
• Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary TractCompletedNCT00112671Phase 2Results posted
• A Treatment Combination for Patients With Unresectable Stage III or Stage IV MelanomaCompletedNCT00111007Phase 3Results posted
• Treatment for Subjects With Unresectable Stage III or Stage IV MelanomaCompletedNCT00110994Phase 2Results posted
• Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT00110019Phase 3Results posted
• A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic MalignanciesCompletedNCT00109707Phase 1/2Results posted
• A Research Study to Treat Patients With Advanced Hepatocellular CarcinomaCompletedNCT00108953Phase 2Results posted
• Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract CancerCompletedNCT00107536Phase 2Results posted
• A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant PatientsCompletedNCT00106639Phase 2Results posted
• A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaCompletedNCT00105443Phase 3Results posted
• Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular CorrelatesTerminatedNCT00104728Not applicableResults posted
• Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid LeukemiaCompletedNCT00103844Phase 2Results posted
• Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate CancerCompletedNCT00103194Phase 2Results posted
• Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib MesylateCompletedNCT00101816Phase 2Results posted
• Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to ImatinibCompletedNCT00101660Phase 2Results posted
• Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid LeukemiaCompletedNCT00101647Phase 2Results posted
• BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)CompletedNCT00101413Phase 2Results posted
• BAY43-9006 - Phase II in Advanced Breast CancerCompletedNCT00101400Phase 2Results posted
• Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By SurgeryCompletedNCT00101036Phase 2Results posted
• Efficacy and Tolerability of ZD6474 in Patients With Thyroid CancerCompletedNCT00098345Phase 2Results posted
• BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung CancerCompletedNCT00098254Phase 2Results posted
• Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung CancerCompletedNCT00096486Phase 1/2Results posted
• Lapatinib in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00096447Phase 2Results posted
• Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung CancerTerminatedNCT00096265Phase 3Results posted
• Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT00096200Phase 2Results posted
• Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System TumorsCompletedNCT00095940Phase 1/2Results posted
• Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine TherapyCompletedNCT00095836Phase 2Results posted
• Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland CancersCompletedNCT00095563Phase 2Results posted
• Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic MelanomaCompletedNCT00094107Phase 2Results posted
• Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00094094Phase 2Results posted
• Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid CancerCompletedNCT00094055Phase 2Results posted
• Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic CancerCompletedNCT00091026Phase 2Results posted
• Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's SarcomaCompletedNCT00090987Phase 2Results posted
• A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate CancerCompletedNCT00090545Phase 2Results posted
• Lapatinib In Chemotherapy-Naive Or Metastatic Breast CancerCompletedNCT00089999Phase 2Results posted
• SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell CarcinomaCompletedNCT00089648Phase 2Results posted
• Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck CancerTerminatedNCT00088907Phase 3Results posted
• S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast CancerCompletedNCT00087152Phase 2Results posted
• Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast CancerCompletedNCT00086957Phase 1/2Results posted
• Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2CompletedNCT00085839Phase 2Results posted
• Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate CancerCompletedNCT00085566Phase 1/2Results posted
• SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell CarcinomaCompletedNCT00083889Phase 3Results posted
• A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.CompletedNCT00077974Phase 2Results posted

← Tyrosine Kinase Inhibitors overview